Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: TAK-981
Drug: Rituximab

First Posted Date: 2019-08-30

Last Posted Date: 2024-06-14

Lead Sponsor: Takeda

Target Recruit Count: 38

Registration Number: NCT04074330

Locations: 🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 56 locations

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab (Genetical Recombination)

First Posted Date: 2019-06-28

Last Posted Date: 2024-07-10

Lead Sponsor: Takeda

Target Recruit Count: 335

Registration Number: NCT04002180

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Biological: Placebo

First Posted Date: 2019-06-27

Last Posted Date: 2024-05-31

Lead Sponsor: Takeda

Target Recruit Count: 365

Registration Number: NCT03999996

Locations: 🇺🇸
AES - DRS - Synexus Clinical Research US, Inc. Minneapolis, Richfield, Minnesota, United States
🇺🇸
Advanced Clinical Research/Velocity Clinical Research, West Jordan, Utah, United States
🇲🇽
Instituto Nacional de Pediatria, Ciudad De Mexico, Mexico

and more 7 locations

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: TAK-079
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Pomalidomide

First Posted Date: 2019-06-12

Last Posted Date: 2024-04-30

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT03984097

Locations: 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Pacific Cancer Care, Monterey, California, United States

and more 6 locations

Perianal Fistula (PAF) Validation and Burden of Illness Study

Completed

Conditions: Crohns Disease
Perianal Fistula
Inflammatory Bowel Disease

Interventions: Other: No intervention

First Posted Date: 2019-06-11

Last Posted Date: 2021-04-21

Lead Sponsor: Takeda

Target Recruit Count: 3032

Registration Number: NCT03981939

Locations: 🇨🇦
Takeda Canada, Oakville, Ontario, Canada

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-23

Last Posted Date: 2019-11-14

Lead Sponsor: Takeda

Target Recruit Count: 204

Registration Number: NCT03961308

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-23

Last Posted Date: 2019-11-13

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03961295

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-14

Last Posted Date: 2022-07-29

Lead Sponsor: Takeda

Target Recruit Count: 102

Registration Number: NCT03948581

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-14

Last Posted Date: 2019-11-13

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03949621

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Drug: TAK-018 Placebo
Drug: TAK-018

First Posted Date: 2019-05-09

Last Posted Date: 2023-09-07

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT03943446

Locations: 🇫🇷
Hopital Saint-Louis, Paris Cedex 10, Il-de-France, France
🇫🇷
Centre Hospitalier Universitaire de Nice Hopital l'Archet, Nice Cedex 3, Provence Alpes Cote D'Azur, France
🇺🇸
University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy